Chongqing Pharscin Pharmaceutical (SHE:002907) obtained extensions for production authorization for esomeprazole sodium injection and vitamin D drops from the Chongqing regulator.
The drug manufacturing licenses are now valid until November 2026 for esomeprazole sodium and June 2030 for vitamin D drops, according to a Friday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments